Aims: Merkel cell carcinoma, a rare cutaneous neuroendocrine tumour of the skin, can be categorised into two groups according to Merkel cell polyomavirus (MCV) presence. MCV-negative tumours are more aggressive and frequently associated with gene mutations. Some of the genes are potential therapeutic targets. We have previously reported EGFR mutations in six of 27 MCC tumours and overexpression of ALK and EZH2 at mRNA level in MCC tumours. In this study, we sought to determine expression of ALK, EGFR and EZH2 in MCC samples and assess their correlation to MCV status and clinical parameters. Methods and results: Tissue microarrays were utilised and stained with primary antibodies. Staining data were statistically compared to patient sex, tumour location and development of metastasis and MCC-specific death; 112 tumours and their corresponding patient data were included. We found strong expression of ALK in 51% and strong expression of EZH2 in 76% of the tumours. There was evident correlation of ALK expression with MCV-positivity. Expression of EGFR was infrequent, presenting only in seven MCVnegative tumours. None of the proteins associated with development of metastasis or MCC specific death. Conclusions: ALK and EZH2 expression are frequent in MCC and ALK expression correlates to MCV positivity. EGFR positive tumours might respond to EGFR inhibiting treatment.
Introduction
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer categorised into two groups according to the presence of the Merkel cell polyomavirus (MCV). [1] [2] [3] [4] MCC has a tendency to metastasise; it spreads to the lymph nodes more often than other skin malignancies. 5 Notably, MCV-negative tumours seem to be more aggressive compared with MCV-positive tumours. 6, 7 We have previously studied MCC tumours for aberrations in cancer-related genes utilising targeted nextgeneration sequencing (NGS). The most intriguing findings of our NGS studies were mutations of the EGFR gene in 22% of 27 MCC tumours, and overexpression of ALK and EZH2 at mRNA level in MCC tumours compared to normal skin. 8, 9 Most of the EGFR mutations we detected have been previously reported in non-small-cell lung cancer, 10 and at least one of the mutations has been reported to be responsive to EGFR inhibitor treatment in lung adenocarcinoma. 11 EGFR and ALK are transmembrane receptor tyrosine kinases involved in many types of cancer; for example, non-small-cell lung cancer. [12] [13] [14] [15] [16] ALK is named after its involvement in a fusion protein discovered in anaplastic large cell lymphomas. 17 There is no evidence of activating ALK mutations 8, 18, 19 or fusions 9, 20 in previous literature regarding MCC, and therefore the mechanism of ALK overexpression is unknown. EZH2 is an enzyme that silences gene function by promoting DNA heterochromatin formation. It is normally expressed during fetal development, but expression of EZH2 is found in various types of cancer and the role of EZH2 inhibitors in cancer therapy is under investigation with multiple ongoing preclinical projects, 21 while at least one Phase I study regarding B cell lymphoma and epithelioid sarcoma is completed. 22 MCV-positive and -negative tumours have distinct pathological characteristics; therefore, it is rational to seek molecular aberrations in subsets of MCC tumours that would potentially benefit from certain targeted therapy. Mutational studies indicate that MCV-negative tumours in particular are associated with more gene mutations, the majority of which are caused by ultraviolet (UV) radiation. For certain MCC tumours, some of these mutated genes are considered potential targets of therapy. 8, 18, 19, 23 Based on our previous results, in the current study we sought to determine expression of ALK, EGFR and EZH2 by immunohistochemistry in a large tumour cohort and assess their correlation to the tumour MCV status and potential prognostic or therapeutic value of these proteins.
Materials and methods
The Ethics Committee of Helsinki University Hospital approved the study. The Ministry of Health and Social Affairs granted permission to collect patient data, and the National Authority granted permission for Medicolegal Affairs to collect and analyse tumour samples. Clinical data collected for this study included patient age at diagnosis, sex, location of primary tumour and information on whether the patient developed metastasis or died of MCC. The clinical details were collected for these patients as they were on 12 June 2013, and no further follow-up was conducted.
Tissue microarrays (TMA) were constructed from our nationwide pool of formalin-fixed paraffinembedded (FFPE) MCC tumour samples. MCC diagnoses were confirmed by clinical characteristics and microscopic morphology compatible with cutaneous MCC and by immunohistochemistry positive for CK-20 and negative for TTF-1. MCV status of the tumours was determined by quantitative polymerase chain reaction (PCR), as described in detail elsewhere. 24 From the FFPE tumour samples, representative tumour regions were first defined from haematoxylin and eosin (H&E)-stained sections and marked. A 0.6-mm tissue core of each tumour sample was inserted into an empty well on the tissue array block. Two cores per tumour were included at initial construction. Three lm sections were cut from the TMA block and processed for immunohistochemistry.
For immunohistochemical staining, a Ventana Benchmark Ultra instrument (Roche, Tucson, AZ, USA) was utilised for ALK-1 (clone D5F3, Roche 790-4794) and EGFR (clone 5B7; Roche 790-4347) ready-to-use (RTU) antibodies. For pretreatment of these antibodies we used cell conditioning 1 buffer, pH 8.5 (Roche 950-124) for 64 min at 98°C. The incubation time for ALK-1 was 28 min/36°C and for EGFR was 20 min/36°C. The multimer-based detection kit, OptiView (Roche 760-700) was used to detect the antibodies. An amplification step was added for both protocols using separated an amplification kit (Roche 760-099). Lung adenocarcinoma tissue with EML4-ALK translocation confirmed by fluorescence in-situ hybridisation (FISH) as well as anaplastic large cell lymphoma tissue with NPM1-ALK translocation confirmed by FISH was used as a positive control for ALK staining, while the negative controls were lung adenocarcinoma and ALCL samples without the mentioned chromosome rearrangements. For EGFR, normal epidermis and human placenta were used as positive controls. The EZH2 staining (clone 11/EZH2, BD Transduction 612666; BD Biosciences, San Jose, CA, USA) was performed in the LabVision immunostainer (Labvision, Fremont, CA, USA). Antigen retrieval was performed using the Tris-ethylenediamine tetraacetic acid (EDTA) buffer, pH 9.0 (in a PT-module for 20 min at 98°C). For detection, we applied the polymer-based detection system (Envision, K5007; Agilent, Santa Clara, CA, USA). Diaminobenzidine (DAB) was applied as a chromogen for all the antibodies and the slides were stained with haematoxylin (Mayer, S3099; Agilent).
Immunohistochemical staining was interpreted by two researchers (T.V. and T.B.). Individual samples on the TMA slides were disqualified if the sample was partly or completely missing, or technically excluded during the construction process if the sample did not include tumour tissue or the MCV status of the tumour was unknown. The exact number of included samples varied from 110 to 111 between stained TMA slides, but altogether there were 112 tumours that had successful staining with at least two of the antibodies and were therefore included in the further analysis. Regarding ALK and EZH2 immunohistochemistry (IHC), there was large variation of staining intensity between individual samples, and thus, based on the intensity of staining, expression of ALK and EZH2 was interpreted as either negative, weakly positive or strongly positive (Figures 1 and 2 ). In contrast, EGFR expression was simply interpreted as either negative or positive (Figure 3) .
Statistical analysis to correlate protein expression to MCV status and clinical data was performed with the v 2 and Fisher's exact tests. The v 2 test was also utilised to correlate the presence of metastasis during the follow-up to MCC-specific death. To analyse the relationship of protein expression and MCC-specific death, survival was estimated with the Kaplan-Meier method and the log-rank test was used to compare survival between the groups. MCC-specific survival was calculated from the date of diagnosis to date of death from MCC. P-values less than 0.05 were considered significant. Statistical analysis was performed with NCSS statistical software (NCSS, LCC, Kayesville, UT, USA). The Kaplan-Meier plots are presented in the Supporting Information Figures S1-S3 .
Results
This study included TMAs containing 112 Merkel cell carcinoma tumour samples with respective clinical data. Of those 112 patients, 30 (27%) were male and 82 (73%) female. The mean age of the patients was 78 years. More than half the tumours (60, 54%) were located in the head and neck region. Thirty-one tumours were MCV-negative (28%) and 81 MCVpositive (72%). Distant metastasis was present in 28 cases (25%), while 11 cases (9.8%) had only local lymph node involvement. At the end of follow-up for this patient cohort, 20% had died from MCC. The presence of distant metastasis during the follow-up was significantly correlated to MCC specific death (P < 0.00001). Immunohistochemical staining results in comparison to MCV status is presented in Table 1. A L K E X P R E S S I O N ALK expression was analysed successfully in 110 tumour samples. Two of the tumours had corrupted ALK staining on the TMA slides. From the 110 tumours, 56 were strongly positive for ALK and 16 weakly positive (51 and 15%, respectively). Thirtyeight (34%) tumours were negative for ALK (Figure 4) .
We recorded a clear correlation between ALK expression and MCV positivity; from the 79 MCVpositive tumours, 62 were positive for ALK (78%) and 65% were strong positives, while in the MCVnegative cohort only 10 of 31 tumours were ALKpositive (32%) and 16% were strong positives. This correlation between ALK expression and MCV positivity was statistically significant (P = 0.000006). However, ALK expression did not correlate with patient sex, tumour location or development of metastasis or MCC-specific death.
E G F R E X P R E S S I O N
A total of 111 tumours were analysed for EGFR, and only seven (6.3%) were positive. Notably, all EGFRpositive tumours were MCV-negative and 23% of the 31 MCV-negative tumours expressed EGFR (P = 0.000011 and P = 0.000077, respectively) (Figure 5 ). We were unable to find a significant correlation with EGFR expression to sex, location, metastasis or MCC-specific death, although there was a slight trend to a more severe course of disease, as three of seven EGFR-positive tumours developed metastasis and died from MCC. However, this observation was not statistically significant.
E Z H 2 E X P R E S S I O N
Our examination revealed abundant expression of EZH2 in MCC tumours. Eighty-four of 111 tumours (76%) showed strong positivity, while 18 (16%) tumours were weakly positive and only nine (8%) were negative. EZH2 expression was not related to tumour MCV status or any of the clinical parameters that were analysed.
Discussion
In this work, we studied the immunohistochemical expression of ALK, EGFR and EZH2 in 112 Merkel cell carcinoma TMA cores. We showed that ALK expression is common in MCC, although less frequent than previously reported. The intensity of ALK expression seemed to vary between the ALK-positive samples. We did not establish a correlation between ALK immunopositivity and clinical characteristics. However, we showed an evident correlation of ALK expression and tumour MCV positivity. This correlation was particularly apparent with tumours that expressed strong ALK positivity, as 91% were MCVpositive. It is uncharted whether ALK and MCV are interacting, but it could be that the MCV promotes ALK expression via an unknown mechanism.
We have previously studied ALK in MCC tumours and found strong expression of ALK at mRNA and protein level. 9 In our previous study, we applied FISH to seek for chromosomal translocations, but no fusions of ALK were uncovered. 9 ALK expression has been frequent in MCC in previously conducted immunohistochemistry studies; however, no correlation has been reported with tumour MCV status. Filtenborg-Barnkob et al. reported ALK expression frequency as high as 93.8% in 32 MCC tumours, and our group also recorded ALK positivity in 22 of 24 MCC tumours examined (91.7%). 9, 20 Based on the available literature, MCC tumours lack EGFR expression. 25 In our previous studies we recorded underexpression of EGFR at mRNA level in MCC tumours compared to normal skin, 9 and in keeping with other work found no immunohistochemical EGFR positivity in any of the MCC tumours studied. However, we discovered EGFR mutations in 22% of 27 MCC tumours. 8 This encouraged us to explore the expression of EGFR in a larger tumour collection. In this paper we demonstrate that a small number of MCC (6%) were EGFR-positive and, significantly, all were MCV-negative. We even observed a possible association between EGFR positivity and metastasis development and death from MCC, but the association was not statistically significant. As the low number of EGFR-positive cases poses a challenge in analysing correlations to clinical data, more numerous tumour cohorts are required to further assess this potential correlation.
In contrast to our previous study, where we did not find EGFR positivity in MCC tumours by IHC with the antibody clone 31G7, which reacts with the extracellular domain of EGFR, 8 we used a different EGFR antibody (clone 5B7), which binds to the intracellular domain of EGFR and also detects truncated forms of the receptor that are constitutively active. 26 Clone 5B7 has been used to detect expression of EGFR in non-small-cell lung cancer TMA samples and was found to predict response to EGFR tyrosine kinase inhibitor treatment. 26, 27 We therefore suggest that the small subset of MCC tumours that are EGFR-positive and MCV-negative might benefit from EGFR inhibitor treatment, and could be identified with a relatively easy and cost effective-method such as IHC.
We have reported EZH2 expression earlier at mRNA level in MCC tumours. 9 In addition, there has been activating EZH2 mutation in one MCC tumour of 15 tumours studied; 28 however, other mutational studies on MCC have not recorded EZH2 mutations. 8, 18, 19 A recent study by Harms et al. suggested that EZH2 could be a prognostic factor in MCC. Higher expression of EZH2 correlated with worse 5-year MCC-specific survival. 29 Corresponding to their study, we observed frequent expression of EZH2 in MCC tumours (92%) and the intensity of the expression varied between the tumours. Therefore, we categorised the positivity as either weak or strong. However, our cohort also displayed 8% of completely negative tumours. Contrary to Harms et al., we only examined primary MCC tumours, while their cohort included tumour metastases. We did not identify a correlation between primary tumour EZH2 expression and the development of metastasis or MCC-specific death. Therefore, the usability of EZH2 as a prognostic factor is as yet uncertain. However, as the majority of MCC tumours are EZH2-positive it could be a potential therapeutic target, and clinical trials with forthcoming EZH2 inhibitors would be recommended.
A current trend in cancer research and treatment is to investigate individual tumour characteristics more deeply, and develop personalised treatment for cancer patients. 30 Conventional drug trials conducted in large patient cohorts fail to demonstrate efficacy of treatments that only affect a certain group of patients. A particular challenge with MCC is that first, it is rare, and secondly, part of the tumours are associated with MCV and therefore embody distinct pathological properties. Gaining knowledge of genetic and molecular alterations in MCV-positive and -negative tumours creates an opportunity to determine tumours that might benefit from already existing treatments, such as tyrosine kinase inhibitors. Our vision is that future clinical trials for advanced MCC should take into account the individual molecular characteristics of the tumour.
We conclude that protein expression in MCV-positive and -negative tumours is diverse, and also differs in individual tumours. ALK expression correlates to MCV-positivity, while EZH2 expression is frequent regardless of MCV status. A subset of MCV-negative tumours express EGFR and might respond to EGFR TKI treatment.
